Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV

(2020) Jared S. Morse et al.   CHEMBIOCHEM

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

(2020) Guangdi Li et al.   NATURE REVIEWS DRUG DISCOVERY

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthesis of [18F]Favipiravir and Biodistribution in C3H/HeN Mice as Assessed by Positron Emission Tomography

(2019) Thomas M. Bocan et al.   Scientific Reports

Aldehyde Oxidase and Its Role as a Drug Metabolizing Enzyme

(2019) Deepak Dalvie et al.   PHARMACOLOGY & THERAPEUTICS

Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery

(2019) Nenad Manevski et al.   JOURNAL OF MEDICINAL CHEMISTRY

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

(2017) Yousuke FURUTA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

(2017) Thi Huyen Tram Nguyen et al.   PLoS Neglected Tropical Diseases

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

(2016) Vincent Madelain et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)—Sierra Leone, 2014

(2016) Chang-Qing Bai et al.   CLINICAL INFECTIOUS DISEASES

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

(2016) Vincent Madelain et al.   CLINICAL PHARMACOKINETICS

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

(2016) Daouda Sissoko et al.   PLOS MEDICINE

Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen

(2015) Yanli Zhao et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dose regimen of favipiravir for Ebola virus disease

(2015) France Mentré et al.   LANCET INFECTIOUS DISEASES